T-cell receptor recognizing peptide–major histocompatibility complex (TCR (when referring to T-cell receptor))

The **T-cell receptor recognizing peptide–major histocompatibility complex** refers to the molecular interaction between a clonally unique heterodimeric protein complex on the surface of a cytotoxic T lymphocyte and a specific antigenic peptide bound within the groove of an MHC class I molecule displayed on a target cell. The canonical structure is an αβ heterodimer associated with CD3 signaling subunits. This recognition event is central to adaptive immunity, enabling detection and elimination of infected or malignant cells[1][2][3][4][5]. Upon binding its cognate peptide-MHC complex, the cytotoxic T cell becomes activated through intracellular signaling cascades initiated by phosphorylation events in CD3 ITAM motifs, ultimately resulting in targeted killing via cytokine secretion and release of lytic granules[5]. The phrase "Cytotoxic T-cell receptor recognizing peptide-MHC complex on target cancer cell" describes an *interaction* rather than a single molecular entity. The actual therapeutic target is typically either the *peptide-MHC complex* itself or the *T-cell receptor* with defined specificity. For structured data purposes, it is more accurate to refer specifically to "T-cell receptor" or "peptide–MHC complex," not their interaction as one molecule. If you are seeking information about engineering therapeutics that exploit this axis—such as adoptive transfer using engineered receptors—the relevant targets would be either tumor-specific pMHC complexes or genetically modified versions of the native human αβ-TCR. If you need structured data for drug discovery databases, use “T-cell receptor” as canonical name; if your focus is immunotherapy targeting tumor antigens presented by MHC molecules, specify “peptide-major histocompatibility complex.”

Other names

TCR recognizing peptide–MHCCytotoxic T-cell receptorCD8+ T-cell receptor (for cytotoxic subset)αβ T-cell receptor (most common form)

Recognition of specific antigenic peptides presented by MHC molecules on target cells, leading to activation of cytotoxic responses including release of perforin and granzymes[5].